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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.001Telomere shortening necessitates that tumor cells activate a telomere maintenance mechanism (TMM)
to support immortalization. Although most tumor cells activate expression of the enzyme telomerase,
some cells elongate telomeres in a telomerase-independent manner, termed alternative lengthening of
telomeres (ALT). Previous studies have evaluated the presence of telomerase or ALT mechanisms or both
in a variety of tumor types. Our studies also show that TMMs are not mutually exclusive in some tumors.
In contrast, our IHC analyses of human sarcomas identiﬁed a subset of tumors with some cells con-
taining ALT-associated PML bodies, a hallmark of ALT, and separate cells expressing telomerase in the
same tumor. By using a second set of human osteosarcomas, we merged IHC and biochemical analyses
to characterize more fully the tumor TMM. The IHC data reveal the presence of both telomerase- and
ALT-positive tumor cells in samples that demonstrate characteristics of both telomerase and ALT in
biochemical assays. These assays, which measure telomere length and telomerase activity of tumor
extracts, are conventionally used to classify tumor TMM. Our results suggest that TMM is not a single or
perhaps static characteristic of some tumors and that TMM heterogeneity should be considered in tumor
stratiﬁcation. Furthermore, clinical interest in telomere-based therapies may necessitate accurate
characterization of tumor TMM before treatment to maximize therapeutic efﬁcacy. (Am J Pathol 2013,
182: 41e48; http://dx.doi.org/10.1016/j.ajpath.2012.10.001)Supported by The Ohio State University Pelotonia Fellowship Program
(A.R.S.G.), the Bloom’s Syndrome Foundation (J.G.), and NIH grant
CA-117898 (J.G.).Activation of a telomere maintenance mechanism (TMM) is
critical for tumor cell immortalization and cancer progression
because telomeres shorten with each round of cellular divi-
sion. Cells can use two known TMMs: catalytic activity of the
enzyme telomerase or a telomerase-independent, recombi-
nation-based pathway termed alternative lengthening of
telomeres (ALT). In contrast to cells with active telomerase,
cells that use ALT are characterized by long, heterogeneous
telomere lengths, ALT-associated PML bodies (APBs), and
extrachromosomal telomeric repeats. Several studies have
evaluated TMMs in human tumors1,2 and demonstrated that
ALT is overrepresented inmesenchymal tumors,2e12 perhaps
reﬂective of a lack of detectable telomerase expression in
mesenchymal stem cells.13 More speciﬁcally, almost 60% of
osteosarcomas exhibit ALT characteristics,3e6 the highest
incidence of any tumor yet evaluated. In contrast, epithelialstigative Pathology.
.tumors more often express telomerase,1,2 suggesting there
may be cell-speciﬁc preferences for TMM.
Studies have demonstrated that either type of TMM can
occur within the same cell, but only with experimental
manipulation. Exogenous expression of functional telomerase
within some ALT cell lines results in telomerase-mediated
elongation of short telomeres, although cells still retain ALT
characteristics14e16; studies in other ALT cell lines have
shown that telomerase expression inhibits ALT characteris-
tics.17 Fusion experiments of telomerase-expressing and ALT
cells have shown that the mechanisms governing telomere
maintenance are complex. Some telomerase-expressing cells
Table 1 Analysis of TMM in Human Sarcoma TMAs
Patient no. Age (years) Sex Tumor Site Stage TNM grading ALT (%) Tel (%)
1 30 M Chondrosarcoma Leg ND ND 0 95
2 39 F Chondrosarcoma Scapula ND ND 0 95
3 42 F Chondrosarcoma ND ND T2N0M0 0 75
4 49 F Chondrosarcoma ND ND T2N0M0 0 75
5 28 F Chondrosarcoma ND ND T2N0M0 0 40
6 33 M Chondrosarcoma ND ND T1N0M0 0 40
7 52 M Chondrosarcoma ND ND T1N0M0 0 40
8 42 F Chondrosarcoma ND ND T2N0M0 0 33
9 35 F Chondrosarcoma ND ND T2N0M0 0 32
10 38 M Chondrosarcoma ND ND T2N0M0 0 30
11 46 F Chondrosarcoma ND ND T2N0M0 41 0
12 35 M Chondrosarcoma Humerus ND ND 29 0
13 16 F Chondrosarcoma Femur ND ND 5 0
14 42 M Chondrosarcoma ND ND T2N0M0 29 79
15 40 M Chondrosarcoma ND ND ND 25 53
16 33 M Chondrosarcoma ND ND T2N0M0 12 33
17 38 M Chondrosarcoma Face ND ND 9 66
18 58 F Chondrosarcoma ND ND T2N0M0 6 34
19 28 M Chondrosarcoma ND ND T1N0M0 5 85
20 40 M Chondrosarcoma ND ND T2N0M0 2 82
21 34 M Chondrosarcoma Leg IIb T2N0M0 1 3
22 62 M Chondrosarcoma Maxilla ND ND 1 2
23 65 M Chondrosarcoma ND ND T2N0M0 0 0
24 29 M Chondrosarcoma ND ND T1N0M0 0 0
25 48 F Chondrosarcoma ND ND T2N0M0 0 0
26 24 F Chondrosarcoma ND ND T1N0M0 0 0
27 52 F Osteoclastoma ND II T1N0M0 0 69
28 7 F Osteoclastoma Femur ND ND 11 32
29 34 F Osteoclastoma ND II T1N0M0 5 95
30 32 M Osteoclastoma ND II T1N0M0 2 87
31 41 M Osteosarcoma Femur ND ND 0 95
32 18 M Osteosarcoma Humerus IIb T2N0M0 0 90
33 43 M Osteosarcoma Costal IIb T2N0M0 0 90
34 19 M Osteosarcoma Femur ND ND 0 90
35 40 F Osteosarcoma ND ND T2N0M0 0 74
36 13 M Osteosarcoma ND ND T2N0M0 0 62
37 17 M Osteosarcoma ND ND T2N0M0 0 50
38 64 M Osteosarcoma ND ND T2N0M0 0 38
39 23 M Osteosarcoma ND ND T2N0M0 0 30
40 51 M Osteosarcoma Femur IIIb T2N0M0 0 16
41 13 F Osteosarcoma Femur ND ND 0 14
42 37 M Osteosarcoma ND ND T1N0M0 0 13
43 18 M Osteosarcoma ND ND T2N0M0 20 0
44 15 M Osteosarcoma Femur ND ND 47 24
45 31 M Osteosarcoma ND ND T2N0M0 20 16
46 32 F Osteosarcoma ND ND T2N0M0 17 38
47 19 M Osteosarcoma Leg IIb T2N0M0 15 62
48 29 M Osteosarcoma ND ND T1N0M0 15 11
49 24 M Osteosarcoma Skull IIb T2N0M0 9 2
50 32 F Osteosarcoma ND ND T2N0M0 5 2
51 32 F Osteosarcoma ND ND T2N0M0 4 18
52 30 F Osteosarcoma ND ND T2N0M0 4 10
53 14 F Osteosarcoma Tibia IIIb T2N0M0 3 73
54 37 M Osteosarcoma Femur IIb T1N0M0 3 18
55 14 F Osteosarcoma ND ND T2N0M0 2 48
56 17 M Osteosarcoma Femur IIb T2N0M0 1 40
57 30 M Osteosarcoma ND ND T2N0M0 1 37
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Mosaicism of ALT and Telomerasecontain ALT inhibitors other than telomerase itself, because
only some hybrid cells suppress ALT markers and maintain
telomeres exclusively with telomerase.16 Other experiments
with hybrid cells demonstrate suppression of telomerase
activity and maintenance of telomeres by ALT, suggesting
that some ALT cells contain telomerase inhibitors.18 Similar
observations have not been made in vivo.
Most tumors exhibit characteristics of one TMM.
However, most published studies that have classiﬁed human
tumors have also identiﬁed a subset of tumors not deﬁni-
tively ALT or telomerase positive.3e6,9e12,19e23 These
tumors display ambiguous characteristics regarding telo-
mere length, telomerase activity, or the presence of APBs.
Some tumors have long, heterogeneous telomere lengths,
suggestive of ALT, but exhibit telomerase activity; this
ambiguity confounds accurate TMM characterization.
Furthermore, although previous studies have identiﬁed
tumors exhibiting both telomerase activity and the presence
of APBs,10,11 suggesting that both telomerase and ALT cells
are present in the sample, it has not been demonstrated
whether these results indicate separate cell populations,
inﬁltrating normal cells/normal surrounding tissue, or the
presence of multiple TMMs in one cell. Therefore, we asked
whether human sarcomas could demonstrate mosaicism for
TMM by evaluating tumors at a cellular level.
Materials and Methods
Tumor Samples
Human tumor TMAs (T262, T263, BO241, BO481, and
CO483) were obtained from US Biomax (Rockville, MD).
De-identiﬁed frozen human osteosarcoma samples were
obtained from the Human Tissue Resource Network at The
Ohio State University, Columbus, under Institutional
Review Board protocol 2009 E0409.
TRAP Assay
Frozen tumor samples were mechanically homogenized, and
telomerase activity was measured from extracts using the
TRAPeze kit (Millipore, Billerica, MA), per manufacturer’s
directions. Extracts were pre-incubated with template and
phenol-chloroform extracted to remove endogenous PCR
inhibitors. Products were imaged on a Typhoon Imaging
system (GE Healthcare Biosciences, Pittsburgh, PA). Each
sample was independently analyzed at least ﬁve times.
Positive control immortalized cell lines HeLa and WI38Patient age, sex, tumor diagnosis, site, stage, and pathological TNM grading w
were IHC stained for evidence of TMM by ALT and telomerase. The percentage
telomere/TRF2 and PML, and the percentage of telomerase-positive cells was analy
cells in a ﬁeld, in which some cells expressed neither colocalization of telomere/
F, female; M, male; % ALT, percentage of cells positive for ALT; % Tel, percen
metastasis.
The American Journal of Pathology - ajp.amjpathol.orgVA-13/2RAwere obtained fromATCC (Manassas, VA), and
lysates were prepared per manufacturer’s directions.
Telomere Restriction Fragment Southern Blot Analysis
Frozen tumor samples were mechanically homogenized and
DNA was extracted using the DNeasy kit (Qiagen, Valencia,
CA), per manufacturer’s directions. DNA (2 mg) was digested
with Hinf I and RsaI restriction enzymes (New England
Biolabs, Ipswich, MA), separated by gel electrophoresis,
and transferred to a charged nylon membrane (Hybond,
Pittsburgh, PA). Cross-linked membrane was hybridized
in UltraHyb-oligo (Ambion, Grand Island, NY) with
a 32P-labeled (CCCTAA)3 probe, and products were imaged
on a Typhoon Imaging system (GE Healthcare Biosciences,
Pittsburgh, PA). Each sample was independently analyzed at
least three times. Positive control immortalized cell lines
HeLa andWI38 VA-13/2RAwere obtained from ATCC, and
DNA was prepared as previously described.
IHC Analysis
Tumor samples were formalin-ﬁxed, embedded in parafﬁn
blocks, and cut into sections (4 mm thick) at The Ohio State
University Pathology Core Facility (Columbus, OH). Auto-
mated antibody staining was performed on a Ventana Bench-
mark XT (Roche, Tuscon, AZ) with protease pretreatment.
Manual immunohistochemistry (IHC)andcombinedﬂuorescent
in situ hybridization were performed according to standard
procedures after antigen retrieval by steaming in 10 mmol/L
sodium citrate buffer (pH 6). Telomeres were hybridized with
a Cy3-(TTAGGG) peptide nucleic acid probe (Panagene,
Daejeon, South Korea). For IHC, the antibodies used were as
follows: anti-telomere repeat binding factor 2 (TRF2) (IMG-
124A; Imgenex, San Diego, CA), anti-PML (ab53773;
Abcam, Cambridge, MA), anti-PML (PG-M3; Santa Cruz
Biotechnology, Santa Cruz, CA), and anti-telomerase (Ab-2;
Calbiochem, Billerica, MA). Image capture and analysis were
performed on a Nuance multispectral imaging system (Cam-
bridge Research and Instrumentation, Hopkinton, MA), as
previously described,24 and staining was conﬁrmed on an
Olympus (Center Valley, PA) FV 1000 spectral confocal
microscope. For analysis, at least 200 cells (when possible) from
at least three different geographical positions within each tumor
were analyzed. Positive control immortalized cell lines HeLa
and WI38 VA-13/2RA were obtained from ATCC and stained
with standard immunocytochemical techniques, as previously
described.ere provided with each tissue sample. Four separate human sarcoma TMAs
of ALT-positive cells within each tumor was analyzed by colocalization of
zed by expression of TERT. The percentage of cells was calculated from total
TRF2 and PML nor telomerase staining.
tage of cells positive for telomerase; ND, no data; TNM, tumor, node, and
43
Figure 1 Characterization of TMM in human osteosarcoma lysates using
whole tumor biochemical assays. A: The average telomere length of DNA from
ﬁve frozen human osteosarcomas is measured by TRF Southern blot analysis.
The signal in each lane represents telomeric DNA fragments liberated from
digested genomic DNA. HeLa and WI38 VA-13/2RA are positive controls for
telomerase and ALT cells, respectively. Telomerase-positive cells have
shorter homogeneous telomere lengths, whereas heterogeneous lengths
characterize ALT-positive cells. DNA- and l DNA represent negative controls.
Telomere length is independently conﬁrmed using quantitative real-time PCR
(data not shown). B: Telomerase activity in the same ﬁve human osteosar-
coma lysates is measured using the TRAP assay. A 36-bp internal control
band is present in each lane, with laddered bands beginning from 50 bp
upwards signifying positive telomerase activity. The presence of only the
internal control band suggests telomerase-negative ALT mechanisms. Heat
denaturation serves as a negative control for each extract. HeLa and WI38
VA-13/2RA cell lysates are positive controls for telomerase-positive and ALT-
positive cells, respectively; other positive and negative controls are internal
controls provided by the manufacturer.
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The observation of tumors with characteristics of both
TMMs suggested questions of whether tumors could contain
some cells expressing telomerase and other cells expressing
characteristics of ALT, or whether the same cell could
express both types of telomere-elongating characteristics.
We examined TMMs within human sarcomas, because of
their high prevalence of ALT, using a computationally
enhanced imaging system capable of analyzing three IHC
stains per tumor cell. We analyzed four TMAs that included
57 high-grade sarcomas: 26 chondrosarcomas, 4 osteoclas-
tomas, and 27 osteosarcomas (Table 1). The microarrays
were analyzed for ALT characteristics using colocalization
of PML with the telomere/telomeric proteins to identify
APBs. APBs were identiﬁed in situ by two techniques:
TRF2 and PML chromogenic IHC using an automated
stainer and manual PML ﬂuorescent IHC combined with
telomere ﬂuorescent in situ hybridization. Microarrays were
also stained with antibodies speciﬁc to the reverse tran-
scriptase subunit of telomerase (TERT). All staining was
validated in human immortalized cell lines with known
TMMs: telomerase-positive HeLa cells and ALT-positive
WI38 VA-13/2RA cells (Supplemental Figure S1). Spatial
localization of all three signals was analyzed using
a Nuance multispectral imaging system, which allows
management of a threshold to exclude background staining.
Cells with TRF2/telomere and PML colocalization
excluded telomerase; however, in some tumors, separate
populations of cells within the same tumor stained positive
for telomerase and negative for TRF2/telomere and PML
colocalization.
Of 57 tumors, 4 contained only ALT-positive cells, 23
contained only telomerase-positive cells, and 26 contained
mixed populations of ALT- and telomerase-positive cells; 4
tumors exhibited neither APBs nor telomerase staining.
Those tumors with both TMMs displayed a wide variability
in the proportion of each cell type, ranging from 1% to 47%
ALT positive and from 2% to 95% telomerase positive
(Table 1). Each tumor varied, in that not all cells within
a tissue section were classiﬁed as ALT or telomerase posi-
tive. This might be due to incomplete staining because of
the osseous nature of these tumors, methodological detec-
tion limits, or varying protein expression levels. Within
asynchronous cultures of ALT cells, APBs were not
observed in all cells because their presence is cell cycle
regulated.25 This could explain the incomplete character-
ization of all tumor cells in our samples and would under-
estimate the proportion of ALT-positive cells. Neither
ALT- nor telomerase-positive cells were detected in normal
bone and cartilage tissues, indicating the staining speciﬁcity
(data not shown). Because ALT is not detected in colorectal
cancers,1,2 a human colon cancer TMA was stained as
a negative control. This array included 40 adenocarcinomas,
all of which displayed telomerase expression and no
colocalization of TRF2 and PML signals (data not shown).44Normal thymus tissue also stained positive for telomerase
and negative for ALT colocalization (data not shown).
Our ﬁndings using in situ colocalization and IHC were
validated with solution-based biochemical analysis and
evaluation of an independent set of ﬁve frozen human
osteosarcomas. Telomere characteristics of each tumor were
assessed using whole tumor lysates and single-cell assays.
Whole tumor lysate assays characterized telomere length
and telomerase activity as a general representation of many
cells within the tumor. Telomere length was measured with
TRF Southern blot analysis, and telomerase activity was
measured with the telomere repeat ampliﬁcation protocol
(TRAP) assay. The relative average telomere repeatajp.amjpathol.org - The American Journal of Pathology
Figure 2 In situ analyses of human osteosarcoma sections. A: High-power magniﬁcation confocal micrographs demonstrate PML (red; top panels), TRF2
signals (green; top panels), and TERT signals (white; bottom panels) in DAPI-stained (blue) nuclei of representative tumor sections. ALT-positive tumors exhibit
colocalization (yellow) of PML and TRF2 signals in discrete nuclear foci (top left panel) and a lack of TERT staining (bottom left panel). Telomerase-positive
tumors exhibit both PML and TRF2 nuclear signals without colocalization (top right panel) and TERT staining (bottom right panel). B: Slides are prepared from
ﬁve frozen human osteosarcomas after formalin ﬁxation and parafﬁn embedding and analyzed for TRF2/PML colocalization and for TERT expression using in situ
IHC. H&E-stained reference sections are shown (top panels), along with an analysis of PML/TRF2 colocalization (pseudocolored yellow; middle panels) and
telomerase expression (pseudocolored white; bottom panels). Cells are counterstained with hematoxylin for visualization. Original magniﬁcation, 100 (A);
40 (B). For PML/TRF2 colocalization and telomerase expression, images are pseudocolored and analyzed using Nuance software version 2.4 (Hopkinton, MA).
Mosaicism of ALT and Telomeraselength of each tumor was independently conﬁrmed using
a quantitative real-time PCR26 (data not shown). Long
heterogeneous telomeres, identiﬁed by TRF Southern blot
analysis, and a lack of telomerase activity by TRAP suggestThe American Journal of Pathology - ajp.amjpathol.orgALT mechanisms; conversely, telomerase-positive staining
and shorter, more homogeneous telomere lengths suggest
telomerase-associated mechanisms. The telomerase-positive
human immortalized cell line HeLa and the ALT-positive45
Table 2 Analysis of Telomere Maintenance in Frozen Human
Osteosarcomas
Tumor Sex
Age
(years)
TRF Southern
blot analysis
TRAP
assay In situ IHC (%)
A M 53 Telomerase þ Telomerase (48)
B M 21 Telomerase þ/ Telomerase (2)/ALT (32)
C F 81 ALT  Telomerase (7)/ALT (31)
D M 69 ALT  ALT (65)
E F 22 ALT þ/ Telomerase (6)/ALT (34)
Summary of TMM characteristics in ﬁve frozen human osteosarcomas.
Telomere length was analyzed by TRF Southern blot analysis, telomerase
activity was analyzed by TRAP assay, and single-cell telomerase and ALT
expression was analyzed by in situ IHC. The percentage of cells was
calculated from total cells in a ﬁeld, in which some cells expressed neither
colocalization of TRF2/PML nor telomerase.
F, female; M, male; þ, positive result; , negative result.
Gocha et alhuman immortalized cell line WI38 VA-13/2RA were used
as positive controls for qualitative characteristics of each
TMM. Each of the ﬁve osteosarcomas contained telomeres
that closely corresponded with characteristics of either HeLa
or WI38 VA-13/2RA cells. One of ﬁve human osteosar-
comas (tumor A) displayed short and homogeneous telo-
mere lengths via TRF Southern blot analysis (Figure 1A)
and telomerase activity via TRAP assay (Figure 1B).
Tumors C and D exhibited only ALT phenotypes (Figure 1,
A and B). Tumors B and E provided ambiguous results with
weak and variable telomerase activity (Figure 1B) and
telomere lengths (Figure 1A) that clearly suggested telo-
merase- (tumor B) and ALT- (tumor E) maintained
telomeres.
Single cells within each frozen tumor sample were then
examined for ALT-associated protein colocalization and
telomerase by in situ IHC. After ﬁxing tumor sections in
10% buffered formalin, in situebased co-expression
analyses were performed blinded to the solution-phase
biochemistry data. Tumor sections were stained with
antibodies to PML, TRF2, and telomerase, and analyzed
using the Nuance multispectral imaging system. Colocal-
ization of TRF2 and PML, denoting an ALT cell, appeared
as distinct nuclear foci consistent with the appearance of
APBs. Colocalization was conﬁrmed using confocal
microscopy to ensure that signals were overlapping in the
same focal plane. Examples of confocal micrographs of
individual representative tumor cells are shown in
Figure 2A. Cells scored as ALT-positive demonstrated
colocalization of PML and TRF2 and minimal or no TERT
staining; cells scored as telomerase-positive demonstrated
no colocalization of PML and TRF2 but were positive for
TERT staining. Of cells from tumor A, 48% were telo-
merase positive, whereas none exhibited TRF2/PML
colocalization (Figure 2B); these results corroborated
those from TRF Southern blot analysis and the TRAP
assay. Conversely, tumors C and D contained 31% and
65% of cells, respectively, with colocalization of TRF2/
PML, corroborating whole tumor lysate assays. Tumor D
completely lacked cells with telomerase expression,
whereas tumor C contained some telomerase-positive cells
(Figure 2B). However, tumor C was geographically
heterogeneous, containing distinct areas of weak or robust
staining; this dimorphism could explain the negative
TRAP results for this tumor, even though some
telomerase-positive cells were present. Finally, tumors B
and E, which had mixed results in whole tumor assays,
displayed two separate cell populations: one staining
positive for ALT protein colocalization (32% and 34%,
respectively) and one staining positive for telomerase (2%
and 6%, respectively) (Figure 2B). The TMM results from
all three assays are summarized in Table 2. Independent
and blinded histopathological analyses were performed to
conﬁrm that ALT- and telomerase-positive cells likely
represented two distinct populations of tumor cells, rather
than inﬁltrating normal cells.46Discussion
Our studies with an enhanced imaging system explicitly
demonstrate that some human sarcomas are mosaic for two
types of cells: those that use telomerase and those that use
ALT. The presence of both cell types highlights a novel type
of tumor heterogeneity and suggests that telomere mainte-
nance may not be a static characteristic of all tumors. In
addition, the presence of more than one TMM confounds
accurate tumor assessment using a single method and indi-
cates a need for precise tumor characterization. Our results
also highlight the question of whether individual cells can
switch TMM or whether a cell commits to telomerase-
dependent or telomerase-independent telomere mainte-
nance. Furthermore, we speculate that tumor types, in
addition to sarcomas, may also contain mosaic populations
of cells with regard to TMM.
Previous studies have reported a lower percentage of
tumors that display characteristics of both TMMs than
determined in our studies, which is 50%. Although those
studies have used an either-or approach for the determina-
tion of TMM, we have combined both IHC and biochemical
analyses to gain a more comprehensive view of the TMM
status of some of these tumors. Some tumors contain a small
percentage of ALT-positive or telomerase-positive cells and
would likely be classiﬁed into one category or another with
assays that analyze a tumor extract, such as the TRF
Southern blot analysis or the TRAP assay. In these solution-
phase assays, tumor cells are combined into a quasi-
homogeneous solution, in which a small percentage of one
particular cell type would not be measured. Combining the
results of these assays with a cell-by-cell analysis by IHC
has identiﬁed multiple TMM cell types within one tumor.
The IHC staining of TERT protein does not conﬁrm telo-
merase activity, although it is highly correlated with telo-
merase activity27,28 and implies that those cells are not using
ALT. TERT staining correlates well with TRAP activity in
the subset of four homogeneously stained osteosarcomas for
which IHC and biochemical assays were possible.ajp.amjpathol.org - The American Journal of Pathology
Mosaicism of ALT and TelomeraseTMM can be a prognosticator for patient survival: ALT-
positive glioblastoma multiforme tumors are associated with
a better prognosis,6,22 whereas ALT-positive liposarcomas
are associated with a worse prognosis11 than telomerase-
positive tumors of each type. Recent clinical trials of
telomerase-targeted therapies also underline the clinical
importance of telomere maintenance. Mosaicism of TMM
within human tumors may affect the choice of therapeutic
approaches, because tumors with cells that maintain telo-
meres via more than one mechanism may require combi-
nation therapies to target each type of cell. In addition,
recent work in mouse models demonstrates that inhibition of
telomerase activity after tumor formation promotes the
survival of tumors via the ALT pathway.29 A similar
scenario is likely to occur in mosaic human tumors after
telomerase inhibitor treatment, stressing the value of precise
tumor TMM characterization before treatment and/or treat-
ment with combination therapies that target both telomerase
and ALT.Acknowledgments
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